Health Care

Danaher’s dividend declaration and Goldman Sachs’ buy rating signal confidence in a stable, diversified health‑care equipment business poised for long‑term growth.

Recordati’s Milan rally shows how real‑world evidence on Castleman disease can lift a rare‑disease pharma’s stock, boosting investor confidence and positioning it for long‑term growth.

Boston Scientific Corp. remains a top choice for investors, thanks to its solid fundamentals, diversified portfolio, and strong growth in medical‑device markets.

Explore how Gilead’s Kite sub‑unit’s new bispecific CAR‑T candidates and Yescarta data could reshape oncology reimbursement, margins and investor outlook.

Labcorp Holdings: steady growth, core clinical laboratory services, precision diagnostics, and robust regulatory compliance—maintaining investor confidence and patient‑care impact.

IQVIA Holdings Inc. stays ahead in health‑care by combining clinical services, real‑world analytics, and patient‑retention tools—leveraging data science to boost drug development, market access, and personalized medicine.

Discover how Natera’s acquisition of Foresight and Canaccord’s “Buy” rating boost precision diagnostics and investor confidence.

Read how Sandoz’s acquisition of Just‑Evotec Biologics expands its biosimilar manufacturing power, cuts costs, and boosts market share in the $30 billion industry.

Jiangsu Hengrui expands national insurance coverage, adding oncology and targeted drugs to China’s catalog and innovation directory—boosting access, revenue, and market share.

Genmab’s epcoritamab shows 70‑80% response in follicular lymphoma, with a US NPV of $1.1 B—boosting its value, pricing strategy, and M&A appeal.